16 results on '"Kater, Arnon P."'
Search Results
2. Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.
- Author
-
Kater, Arnon P., Eichhorst, Barbara F., Owen, Carolyn J., Jaeger, Ulrich, Chyla, Brenda, Lefebure, Marcus, Millen, Rosemary, Jiang, Yanwen, Thadani‐Mulero, Maria, Boyer, Michelle, and Seymour, John F.
- Published
- 2024
- Full Text
- View/download PDF
3. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities.
- Author
-
Stamatopoulos, Kostas, Pavlova, Sarka, Al‐Sawaf, Othman, Chatzikonstantinou, Thomas, Karamanidou, Christina, Gaidano, Gianluca, Cymbalista, Florence, Kater, Arnon P., Rawstron, Andy, Scarfò, Lydia, Ghia, Paolo, and Rosenquist, Richard
- Published
- 2024
- Full Text
- View/download PDF
4. Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies
- Author
-
Gopalakrishnan, Sathej, primary, Menon, Rajeev, additional, Suleiman, Ahmed A., additional, Kater, Arnon P., additional, Stilgenbauer, Stephan, additional, Seymour, John F., additional, Chyla, Brenda, additional, Lu, Tong, additional, Young Kim, Su, additional, Roberts, Andrew W., additional, Woyach, Jennifer A., additional, Mensing, Sven, additional, and Salem, Ahmed Hamed, additional
- Published
- 2023
- Full Text
- View/download PDF
5. High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
- Author
-
Hengeveld, Paul J., primary, Kolijn, P. Martijn, additional, Demmers, Jeroen A.A., additional, Doff, Wouter, additional, Dubois, Julie M.N., additional, Rijken, Melissa, additional, Assmann, Jorn L.J.C., additional, van der Straten, Lina, additional, Boiten, Henk Jan, additional, Gussinklo, Kirsten J., additional, Valk, Peter J.M., additional, Faber, Laura M., additional, Westerweel, Peter E., additional, Kater, Arnon P., additional, Levin, Mark-David, additional, and Langerak, Anton W., additional
- Published
- 2023
- Full Text
- View/download PDF
6. In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival
- Author
-
Haselager, Marco V., primary, van Driel, Bianca F., additional, Perelaer, Eduard, additional, de Rooij, Dennis, additional, Lashgari, Danial, additional, Loos, Remco, additional, Kater, Arnon P., additional, Moerland, Perry D., additional, and Eldering, Eric, additional
- Published
- 2023
- Full Text
- View/download PDF
7. S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
- Author
-
Kielbassa, Karoline, primary, Haselager, Marco, additional, Bax, Danique, additional, van Driel, Bianca, additional, Levin, Mark-David, additional, Kersting, Sabina, additional, Svanberg, Rebecka, additional, Niemann, Carsten U., additional, Kater, Arnon P., additional, and Eldering, Eric, additional
- Published
- 2023
- Full Text
- View/download PDF
8. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
- Author
-
Chatzikonstantinou, Thomas, primary, Scarfò, Lydia, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Iacoboni, Gloria, additional, Kotaskova, Jana, additional, Demosthenous, Christos, additional, Alcoceba, Miguel, additional, Al-Shemari, Salem, additional, Aurran-Schleinitz, Thérèse, additional, Bacchiarri, Francesca, additional, Bellido, Mar, additional, Bijou, Fontanet, additional, Calleja, Anne, additional, Medina, Angeles, additional, Khan, Mehreen Ali, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Collado, Rosa, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Santos, Gimena Dos, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, Galitzia, Andrea, additional, García-Serra, Rocío, additional, Gimeno, Eva, additional, González-Gascón-Y-Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Guieze, Romain, additional, Gogia, Ajay, additional, Gupta, Ritu, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Hernández-Rivas, José-Ángel, additional, Inchiappa, Luca, additional, Jaksic, Ozren, additional, Janssen, Susanne, additional, Kalicińska, Elżbieta, additional, Kamel, Laribi, additional, Karakus, Volkan, additional, Kater, Arnon P, additional, Kho, Bonnie, additional, Kislova, Maria, additional, Konstantinou, Εliana, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Levin, Mark-David, additional, Levy, Ilana, additional, Longval, Thomas, additional, Lopez-Garcia, Alberto, additional, Marquet, Juan, additional, Maynadié, Marc, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Murru, Roberta, additional, Nath, Uttam Kumar, additional, Navarro-Bailón, Almudena, additional, Oliveira, Ana C., additional, Olivieri, Jacopo, additional, Oscier, David, additional, Panovska-Stavridis, Irina, additional, Papaioannou, Maria, additional, Papajík, Tomas, additional, Phumphukhieo, Punyarat, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Rani, Lata, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ronson, Aharon, additional, Ruchlemer, Rosa, additional, de Deus Santos, Marcos Daniel, additional, Schipani, Mattia, additional, Schiwitza, Annett, additional, Shen, Yandong, additional, Simkovic, Martin, additional, Smirnova, Svetlana, additional, Sameh Abdelrahman Soliman, Dina, additional, Spacek, Martin, additional, Tadmor, Tamar, additional, Tomic, Kristina, additional, Tse, Eric, additional, Vassilakopoulos, Theodoros, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Tresckow, Julia von, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Walewska, Renata, additional, Wasik-Szczepanek, Ewa, additional, Xu, Zhenshu, additional, Yagci, Munci, additional, Yañez, Lucrecia, additional, Yassin, Mohamed, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria, additional, Antic, Darko, additional, Biderman, Bella, additional, Catherwood, Mark, additional, Claus, Rainer, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Nikitin, Eugene, additional, Pangalis, Gerassimos A., additional, Panagiotidis, Panagiotis, additional, Mulligan, Stephen, additional, Popov, Viola Maria, additional, Pospisilova, Sarka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine, additional, Trentin, Livio, additional, Chatzidimitriou, Anastasia, additional, Bosch, Francesc, additional, Doubek, Michael, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional
- Published
- 2023
- Full Text
- View/download PDF
9. A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors
- Author
-
Janssen, Jerry, primary, Donner, Naomi, additional, Li, Zhen, additional, Wormhoudt, Thera A.M., additional, Wagner, Koen, additional, Guikema, Jeroen E.J., additional, van der Schoot, C. Ellen, additional, Kater, Arnon P., additional, Feizi, Ten, additional, Bende, Richard J., additional, and van Noesel, Carel J.M., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
- Author
-
Hofland, Tom, primary, de Weerdt, Iris, additional, Endstra, Sanne, additional, Jongejan, Aldo, additional, Platenkamp, Laura, additional, Remmerswaal, Ester B.M., additional, Moerland, Perry D., additional, ten Berge, Ineke J.M., additional, Levin, Mark-David, additional, Kater, Arnon P., additional, and Tonino, Sanne H., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Rare but Serious: Ibrutinib Induced Liver Failure
- Author
-
Kleijwegt, Fleur S., primary, Roda, Afnan Abdul, additional, Rolvink, José, additional, Kater, Arnon P., additional, Kersten, Marie José, additional, and Vos, Josephine M.I., additional
- Published
- 2019
- Full Text
- View/download PDF
12. Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling
- Author
-
Hofland, Tom, primary, Endstra, Sanne, additional, Gomes, Calum K.P., additional, de Boer, Renate, additional, de Weerdt, Iris, additional, Bobkov, Vladimir, additional, Riedl, Jurgen A., additional, Heukers, Raimond, additional, Smit, Martine J., additional, Eldering, Eric, additional, Levin, Mark-David, additional, Kater, Arnon P., additional, and Tonino, Sanne H., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
- Author
-
de Weerdt, Iris, primary and Kater, Arnon P., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations.
- Author
-
Baliakas, Panagiotis, Espinet, Blanca, Mellink, Clemens, Jarosova, Marie, Athanasiadou, Anastasia, Ghia, Paolo, Kater, Arnon P., Oscier, David, Haferlach, Claudia, and Stamatopoulos, Kostas
- Published
- 2022
- Full Text
- View/download PDF
15. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
- Author
-
Chatzikonstantinou T, Scarfò L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, de Deus Santos MD, Dimou M, Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Jaksic O, Kalicińska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou Ε, Koren-Michowitz M, Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez-Garcia A, Marquet J, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Nath UK, Navarro-Bailón A, Olivieri J, Panovska-Stavridis I, Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M, Schiwitza A, Shen Y, Shokralla T, Simkovic M, Smirnova S, Soliman DSA, Stilgenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, Vrachiolias G, Vukovic V, Walewska R, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P, Espinet B, Pangalis GA, Popov VM, Mulligan S, Angelopoulou M, Demirkan F, Papajík T, Biderman B, Murru R, Coscia M, Tam C, Cuneo A, Gaidano G, Claus R, Stavroyianni N, Trentin L, Antic D, Smolej L, Kalashnikova OB, Catherwood M, Spacek M, Pospisilova S, Doubek M, Nikitin E, Chatzidimitriou A, Ghia P, and Stamatopoulos K
- Abstract
Competing Interests: Thomas Chatzikonstantinou received honoraria from AbbVie. Lydia Scarfò received honoraria from AbbVie, AstraZeneca, BeiGene, Lilly, Janssen, Octapharma. Gloria Iacoboni received honoraria and travel support from Novartis, Kite/Gilead, Bristol‐Myers Squibb, Abbvie, Autolus, Miltenyi, and AstraZeneca. Rosa Collado received support for attending meetings from Janssen‐Cilag and S.A. Sara Galimberti received honoraria support for attending meetings from AbbVie, AstraZeneca, Jazz, Novartis, and Incyte, honoraria from Roche, Celgene, Pfizer, and Janssen, and support for attending meetings from Jazz, AstraZeneca, and Roche. Romain Guieze received honoraria, consulting fees, and support for attending meetings from AbbVie, Beigene, Roche, Janssen, and AstraZeneca. Eleftheria Hatzimichael received honoraria from AbbVie, Janssen‐Cilag, AstraZeneca, and Roche. Yair Herishanu received honoraria from Janssen, AbbVie, Roche, AstraZeneca, Medion, and Lilly. José‐Ángel Hernández‐Rivas received honoraria as a consultant from Janssen, AbbVie, AstraZeneca, Lilly, and BeiGene and support for attending meetings from Janssen, AbbVie, AstraZeneca, and BeiGene. Ozren Jaksic received honoraria from Johnson and Johnson, AstraZeneca, and Lilly, honoraria from Johnson and Johnson, AbbVie, AstraZeneca, and Lilly, and support for attending meetings from Johnson and Johnson, and AbbVie. Kamel Laribi received consulting fees from AbbVie, AstraZeneca, Janssen, Beigene, Takeda, and Novartis. Maya Koren‐Michowitz received honoraria from Novartis, Pfizer, and Gad Medical LTD. and support for attending meetings from Novartis. Arnon P. Kater received advisory board fees and research money from Janssen, AbbVie, BMS, AstraZeneca, and Roche/Genentech, and support for attending meetings from Janssen and AbbVie. Ioannis Kotsianidis received honoraria and consulting fees from AbbVie and Janssen. Ivana Milosevic received honoraria from AbbVie, Roche, Sandoz, AstraZeneca, and Janssen, and support for attending meetings from AbbVie, Roche, and Takeda. Almudena Navarro‐Bailón received honoraria, advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, Takeda, Janssen, and Beigene. Jacopo Olivieri received honoraria from AbbVie, AstraZeneca, and Janssen. Gianluigi Reda received consulting fees from AbbVie, AstraZeneca, Janssen, and Beigene, and is currently employed by AstraZeneca. Gian M. Rigolin received honoraria for participation in speaker's bureau from AbbVie, Astra Zeneca, Beigene, and Janssen, and support for attending meetings from Janssen. Mattia Schipani received honoraria and support for attending meetings from AstraZeneca, AbbVie, and Janssen‐Cilag and owns shares of stock in AbbVie, AstraZeneca, Merck, Eli Lilly, Sanofi, Johnson and Johnson, Pfizer, Gilead, and GSK. Tereza Shokralla and Stephan Stilgenbauer reports research funding from, consultancy or advisory role for, honoraria from, speakers' bureau participation for, and travel support from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann‐La Roche, Incyte, Infinity, Janssen, Novartis, and Sunesis. Eric Tse received support for attending meetings from Takeda. Theodoros Vassilakopoulos received honoraria from Takeda, Roche, Genesis Pharma, Merck, Novartis, Gilead, Sandoz, AstraZeneca, Integris, and Servier, and support for attending meetings from Takeda, Roche, Genesis Pharma, Merck, Pfizer, and Winmedica. Candida Vitale received honoraria from AbbVie, consulting fees from AstraZeneca, and support for attending meetings from AstraZeneca, Takeda, and Janssen. Renata Walewska received honoraria from AbbVie, AstraZeneca, and Beigene, support for attending meetings from Janssen, AbbVie, and AstraZeneca, and advisory board fees from AbbVie, AstraZeneca, Janssen, Beigene, and SecuraBio. Lucrecia Yañez received honoraria from AbbVie, AstraZeneca, Novartis, Gilead, Janssen, Jazz, MSD, and Pfizer, support for attending meetings from AbbVie, AstraZeneca, Gilead, Janssen, and Pfizer, and advisory board fees from AbbVie, AstraZeneca, Jazz, Janssen, Beigene, and Celgene. Francesc Bosch received consulting fees, honoraria, and payment for expert testimony from AbbVie, Genentech, Novartis, Takeda, Janssen, Roche, Mundipharma, Celgene/BMS, AstraZeneca, Lilly, Beigene, Gilead and TG Therapeutics, Advantage Allogene, Lava Therapeutics, and Enterome. Stephen Mulligan received advisory board fees from AbbVie, AstraZeneca, Janssen, Roche, and BeiGene. Maria Angelopoulou received consulting fees from AbbVie, Takeda, Janssen, Roche, Genesis, Gilead, and Amgen and honoraria from AbbVie, Takeda, Roche, Genesis, Gilead, and Novartis. Fatih Demirkan received support for attending meetings from Janssen and AbbVie. Tomas Papajík received honoraria and advisory board fees from AbbVie, Janssen‐Cilag, and AstraZeneca, and support for attending meetings from AstraZeneca. Marta Coscia received honoraria, advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, and Janssen. Constantine Tam received honoraria from AbbVie, Beigene, Janssen, and LOXO. Antonio Cuneo received honoraria, advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, Beigene, Janssen, and Lilly. Gianluca Gaidano received honoraria from Abbvie, AstraZeneca, BeiGene, Hikma, Incyte, Janssen, and Lilly. Niki Stavroyianni received honoraria from Janssen, AbbVie, AstraZeneca, and Lilly, and support for attending meetings from Janssen and AstraZeneca. Lukas Smolej received consulting fees, honoraria, and support for attending meetings from AbbVie, AstraZeneca, and Janssen and advisory board fees from AbbVie and AstraZeneca. Martin Spacek received honoraria and consulting and advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, and Janssen. Michael Doubek received research support and honoraria from AbbVie, AstraZeneca, and Janssen. Eugene Nikitin received honoraria from AbbVie. Kostas Stamatopoulos received research support from AbbVie, AstraZeneca, Janssen, Novartis, and Roche; honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Lilly, and Janssen. Paolo Ghia received research support from AbbVie, AstraZeneca, BMS, Janssen and honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Genmab, Janssen, Loxo Oncology @Lilly, MSD, Roche, and is an Editor of HemaSphere. Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Jana Kotaskova, Christos Demosthenous, Elisa Albi, Miguel Alcoceba, Salem Al‐Shemari, Thérèse Aurran‐Schleinitz, Francesca Bacchiarri, Sofia Chatzileontiadou, Zadie Davis, Marcos Daniel de Deus Santos, Maria Dimou, Elena Dmitrieva, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Shaimaa El‐Ashwah, Alicia Enrico, Andrzej Frygier, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Sean Harrop, Elżbieta Kalicińska, Volkan Karakus, Bonnie Kho, Maria Kislova, Εliana Konstantinou, Zuzana Kubova, Jorge Labrador, Deepesh Lad, Luca Laurenti, Thomas Longval, Alberto Lopez‐Garcia, Juan Marquet, Stanislava Maslejova, Carlota Mayor‐Bastida, Biljana Mihaljevic, Fatima Miras, Riccardo Moia, Marta Morawska, Uttam K. Nath, Irina Panovska‐Stavridis, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Rosa Ruchlemer, Annett Schiwitza, Yandong Shen, Tereza Shokralla, Martin Simkovic, Svetlana Smirnova, Dina S. A. Soliman, Tamar Tadmor, Kristina Tomic, Andrea Visentin, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Munci Yagci, Mohamed Yassin, Jana Zuchnicka, David Oscier, Alessandro Gozzetti, Panagiotis Panagiotidis, Blanca Espinet, Paolo Sportoletti, Gerassimos A. Pangalis, Viola M. Popov, Bella Biderman, Roberta Murru, Rainer Claus, Livio Trentin, Darko Antic, Olga B. Kalashnikova, Mark Catherwood, Sarka Pospisilova, and Anastasia Chatzidimitriou have no conflict of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
16. Functional Differences Between EBV- and CMV-Specific CD8 + T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL.
- Author
-
Hofland T, de Weerdt I, Endstra S, Jongejan A, Platenkamp L, Remmerswaal EBM, Moerland PD, Ten Berge IJM, Levin MD, Kater AP, and Tonino SH
- Abstract
Acquired T cell dysfunction is a hallmark of chronic lymphocytic leukemia (CLL), and is linked to an increased risk of infections, but also reduced immune surveillance and disappointing responses to autologous T cell-based immunotherapy. The mechanisms of T cell dysfunction in CLL are not well understood. Studying immunity against chronic viruses allows for detailed analysis of the effect of CLL on T cells chronically exposed to a specific antigen. Cytomegalovirus (CMV) reactivations are rare in CLL, which corroborates with preserved CMV-specific T cell function. Epstein-Barr virus (EBV) is another herpesvirus that results in chronic infection, but unlike CMV, is characterized by subclinical reactivations in CLL patients. Since both herpesviruses induce strong CD8
+ T cell responses, but have different clinical outcomes, studying these specific T cells may shed light on the mechanisms of CLL-induced T cell dysfunction. We first analyzed the phenotype of EBV-specific CD8+ T cells in CLL and healthy controls, and found that in CLL EBV-specific CD8+ T cells are in an advanced differentiation state with higher expression of inhibitory receptors. Secondly, CLL-derived EBV-specific CD8+ T cells show reduced cytotoxic potential, in contrast to CMV-specific T cells. Finally, we performed transcriptome analysis to visualize differential modulation by CLL of these T cell subsets. While T cell activation and differentiation genes are unaffected, in EBV-specific T cells expression of genes involved in synapse formation and T cell exhaustion is altered. Our findings on the heterogeneity of antigen specific T cell function in CLL aids in understanding immune-dysregulation in this disease., (Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.